Table 4.
Main characteristics of study population according to SpA classification.
| Axial SpA (n = 22) | Peripheral SpA (n = 14) | p value | |||
|---|---|---|---|---|---|
| Mean ± SD/median (IQR) | N (%) | Mean ± SD/median (IQR) | N (%) | ||
| Age (yrs) | 45 ± 10 | 40 ± 16 | 0.13 | ||
| Age < 45 yrs | 10 (46) | 4 (29) | 0.31 | ||
| Age at uveitis diagnosis (yrs) | 39 ± 9 | 34 ± 20 | 0.14 | ||
| Uveitis diagnostic delay (mo) | 1 (0-34) | 2 (0-8) | 0.61 | ||
| BMI (kg/m2) | 25 ± 6 | 26 ± 5 | 0.58 | ||
| Family history of SpA† | 11 (50) | 6 (43) | 0.68 | ||
| Current smoker | 3 (14) | 6 (43) | 0.048∗ | ||
| Sex | |||||
| M | 9 (41) | 5 (36) | 0.76 | ||
| F | 13 (59) | 9 (64) | |||
| Diabetes mellitus | 0 (0) | 1 (7) | 0.20 | ||
| Dyslipidemia | 4 (18) | 5 (36) | 0.24 | ||
| Hypertension | 1 (4) | 3 (21) | 0.12 | ||
| HLA-B27 | 19 (86) | 11 (79) | 0.54 | ||
| IBP (ASAS criteria) | 22 (100) | 0 (0) | <0.001∗∗∗ | ||
| Enthesitis | 8 (36) | 5 (36) | 0.97 | ||
| Dactylitis | 5 (23) | 2 (14) | 0.53 | ||
| IBD | 0 (0) | 0 (0) | Nd | ||
| Psoriasis | 1 (4) | 2 (14) | 0.30 | ||
| Urethritis/cervicitis | 2 (9) | 3 (21) | 0.30 | ||
| Peripheral arthritis | 6 (27) | 13 (93) | <0.001∗∗∗ | ||
| Ophthalmic evaluation: | |||||
| Uveitis | |||||
| Acute | 8 (36) | 5 (36) | 0.97 | ||
| Recurrent | 14 (64) | 9 (64) | |||
| Uveitis laterality | 9 (41) | 4 (29) | 0.45 | ||
| Hypopyon | 2 (9) | 0 (0) | 0.25 | ||
| Synechiae | 5 (23) | 3 (21) | 0.93 | ||
| Cataract | 4 (18) | 3 (21) | 0.81 | ||
Legend: SpA: spondyloarthritis; SD: standard deviation; IQR: interquartile range; BMI: body max index; M: male; F: female; HLA: human leukocyte antigen; IBP: inflammatory back pain; ASAS: Assessment of SpondyloArthritis international Society; IBD: inflammatory bowel disease. †Family history of AS, psoriasis, reactive arthritis, uveitis, or IBD in a first-degree relative (father, mother, sisters, brothers, and children) or second-degree relative (maternal and paternal grandparents, aunts, uncles, nieces, and nephews).